Search

Pivotal Ruxolitinib Data Shows Promise for Patients with PV.

 

Polycythemia vera (PV) is a chronic, incurable blood cancer with limited treatment options. If uncontrolled, PV can cause serious cardiovascular complications, such as stroke and heart attack.

Read more

Precision Hematology

The Precision Hematology Topics-in-Focus program will promote innovative concepts for diagnostics and innovative clinical trial designs, which should translate into the clinical application of precision hematology.

Read more

Chairs and members

Chair (2024–2027)
Elizabeth Macintyre, Hôpital Necker-Enfants Malades et Université Paris, France
Vice-Chair (2024–2027)
Margarita Guenova, National Specialised Hospital for Active Treatment of Haematological Diseases, Belgium
Steering Committee (2024–2027)
Monika Brüggemann, University Hospital Kiel, Germany (ESHLO)
Francesco Buccisano, Tor Vergata University of Rome, Italy (SWG on Diagnosis…

Read more

EHA Lymphoma Group

The EHA Lymphoma Group (EHA LyG) is a specialized working group that was established in 2014.

Read more

Targeting the B-cell Receptor in Aggressive B-cell Lymphomas

In collaboration with Dr. Lou Staudt, Pharmacyclics and associate investigators, we performed a clinical trial of a very potent inhibitor of Bruton Tyrosine Kinase (BTK) called ibrutinib.

Read more

EHA Bilateral Collaborative Grant review and selection process

1. Eligibility checkAfter the deadline has passed, we'll check your application for completion and compliance with the eligibility criteria.

Read more